<i>N</i>-Acetylcysteine augmentation in refractory obsessive–compulsive disorder

Bhaskara, Sreenivasa

doi:10.1503/jpn.180179

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding suggests increased cycling and utilization of GSH, and strongly points to coupling between oxidative stress and symptom severity in this model and possibly in OCD, thus consistent with human studies (Atmaca et al, 2005;Chakraborty et al, 2009). Consistent with these findings, adjunctive N-acetyl cysteine (NAC), a GSH precursor and glutamate-NMDA receptor modulator (Berk et al, 2013), has been found to exert beneficial effects in OCD as a cotreatment with SRIs Psychopharmacology of OCD: A Preclinical Roadmap (Afshar et al, 2012;Paydary et al, 2016;Bhaskara, 2019). Recent systematic reviews find the available evidence of clinical benefit encouraging but at present weak (Oliver et al, 2015;Smith et al, 2016;Couto and Moreira, 2018).…”

Section: B Probing the Role Of Other Endogenous Processes In Obsessive-compulsive Disordersupporting

confidence: 78%

The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap

et al. 2019

View full text Add to dashboard Cite

Servier and has received research funding from Servier and Lundbeck. Except for income from the primary employer and research funding to B.H.H. from the above-mentioned organizations and agencies, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional services, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

show abstract

Section: B Probing the Role Of Other Endogenous Processes In Obsessive-compulsive Disordersupporting

confidence: 78%

The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap

et al. 2019

View full text Add to dashboard Cite

show abstract

“…There have been five case reports/series published studying NAC in treating OCD. Target doses ranged from 1800–3000 mg/day and results varied from no effect to substantial improvement [ 96 – 101 ].…”

Section: Obsessive-compulsive and Related Disorders (Ocrd)mentioning

confidence: 99%

The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

N -acetyl-L-cysteine (NAC) is a compound of increasing interest in the treatment of psychiatric disorders. Primarily through its antioxidant, anti-inflammatory, and glutamate modulation activity, NAC has been investigated in the treatment of neurodevelopmental disorders, schizophrenia spectrum disorders, bipolar-related disorders, depressive disorders, anxiety disorders, obsessive compulsive-related disorders, substance-use disorders, neurocognitive disorders, and chronic pain. Whilst there is ample preclinical evidence and theoretical justification for the use of NAC in the treatment of multiple psychiatric disorders, clinical trials in most disorders have yielded mixed results. However, most studies have been underpowered and perhaps too brief, with some evidence of benefit only after months of treatment with NAC. Currently NAC has the most evidence of having a beneficial effect as an adjuvant agent in the negative symptoms of schizophrenia, severe autism, depression, and obsessive compulsive and related disorders. Future research with well-powered studies that are of sufficient length will be critical to better understand the utility of NAC in the treatment of psychiatric disorders.

show abstract